In male CF1 mice, intraperitoneal Hup A lowered brain AChE activity at 1 h and reduced seizures in a 6 Hz challenge. In the dose-response experiment, seizures occurred in 4/12 mice at 0.56 mg/kg and 1/12 at 1 mg/kg, versus 12/12 with vehicle. Effects depended on the challenge: 1 mg/kg shortened the latency to flurothyl-induced myoclonic jerks, and 11/13 treated mice died after the generalized seizure while all vehicle-treated mice survived. [3]
Repeated-dose protection also varied by model. CF1 mice receiving 1 mg/kg/day lost 6 Hz seizure protection by day 12 despite continued AChE inhibition. Scn1aRH/+ mice receiving 1 mg/kg/day remained protected on days 7, 14 and 21, but protection was not maintained 24 h after the last injection. The models were tested at different stimulus currents. [3]
Acute brain AChE pharmacodynamics
Animal study · Male CF1 mice, 6–8 weeks old; right brain hemisphere homogenates. [3]
Brain AChE activity was lower 1 h after Hup A administration; this is a pharmacodynamic endpoint.
Conditions shared by the study groups
- Route
- Intraperitoneal injection, 10 mL/kg
- Frequency
- Single administration
- Treatment course
- Brain sampled 1 h after injection
- Vehicle
- 10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
- Acute dose-response
- Model: Male CF1 mice, 6–8 weeks; N = 3–4/dose
Methods and source locations
Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A
Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.
Methods, Animals, Huperzine A administration and Acetylcholinesterase activity; Figure 1C and caption; first Results section
Brain AChE activity relative to vehicle: Ellman spectrophotometric AChE assay with protein quantification; mean ± SEM; one-way ANOVA with Holm–Šídák comparisons. — Methods, Acetylcholinesterase activity; Results, Hup A protects against induced seizures; Figure 1C
Acute dose-response · Methods, Acetylcholinesterase activity; Figure 1C
Acute 6 Hz seizure challenge
Animal study · Male CF1 mice, 6–8 weeks; corneal stimulation at 6 Hz, 44 mA, 0.2-ms pulses for 3 s. [3]
Hup A reduced seizure occurrence and severity in the 6 Hz challenge, with confirmation in a separate cohort.
Conditions shared by the study groups
- Route
- Intraperitoneal injection, 10 mL/kg
- Vehicle
- 10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
- Randomized dose-response
- Model: Male CF1 mice; N = 12
- Frequency: One randomized dose or vehicle each week
- Treatment course: Six weekly challenge sessions; dose 1 h before each challenge
- Separate confirmation cohort
- Model: Male CF1 mice; N = 15/treatment
- Frequency: Acute treatment in a two-trial crossover, one week apart
- Treatment course: Injection 1 h before 44 mA challenge
Methods and source locations
Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A
Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.
Methods, Animals, Huperzine A administration and 6 Hz psychomotor seizure induction; Results first paragraph; Figure 1A–B
Seizure occurrence: Modified Racine scale; randomized within-mouse dose sequence with weekly challenges. — Methods, 6 Hz psychomotor seizure induction; Results first paragraph; Figure 1A
Complete seizure protection in separate cohort: Modified Racine scale; one-way repeated-measures ANOVA as reported, Dunn post-hoc; Figure 1B p < 0.001. — Results second sentence group; Figure 1B and caption
Randomized dose-response · Methods, 6 Hz psychomotor seizure induction; Figure 1A
Separate confirmation cohort · Methods, 6 Hz psychomotor seizure induction; Figure 1B and corresponding Results
Adverse response in the flurothyl seizure model
Animal study · Male CF1 mice, 6–8 weeks; inhaled flurothyl introduced at 20 μL/min. [3]
Hup A shortened latency to the first myoclonic jerk and did not significantly change latency to generalized tonic-clonic seizures with hindlimb extension. Deaths occurred in 11/13 Hup A-treated mice; all vehicle mice survived.
Conditions shared by the study groups
- Route
- Intraperitoneal injection, 10 mL/kg
- Frequency
- Single administration
- Treatment course
- Injection 1 h before flurothyl exposure
- Vehicle
- 10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
- Flurothyl challenge
- Model: Male CF1 mice; N = 13–15/treatment
- Reported limits: No drug PK or numerical latency values extracted; flurothyl latency test name differs between Methods and caption.
Methods and source locations
Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A
Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.
Methods, Flurothyl seizure induction; Figure 1F–G and caption; Results paragraph beginning Contrary to the robust Hup A-mediated protection
Myoclonic jerk and GTCS-HLE latencies: Behavioral observation after flurothyl infusion; mean ± SEM. Figure 1F caption specifies unpaired Student’s t-test; Methods lists one-way ANOVA for flurothyl. Test-label discrepancy retained; no numerical latency estimated. — Methods, Flurothyl seizure induction and Statistical analyses; Figure 1F–G and caption
Death after GTCS-HLE: Observed after the induced seizure; no mortality p value supplied in the Results sentence. — Results, paragraph beginning Contrary to the robust Hup A-mediated protection
Flurothyl challenge · Methods, Flurothyl seizure induction; Figure 1F–G; corresponding Results
Repeated-dose 6 Hz protection and loss of effect
Animal study · Male CF1 mice and male Scn1aRH/+ mice (3–5 months, C57BL/6J background); different stimulus currents used for the two models. [3]
Protection during daily dosing depended on the model. CF1 mice lost protection, whereas Scn1aRH/+ mice remained protected on days 7, 14 and 21; protection was not maintained 24 h after the final dose.
Conditions shared by the study groups
- Route
- Intraperitoneal injection, 10 mL/kg
- Frequency
- Daily
- Vehicle
- 10% 2-hydroxypropyl-β-cyclodextrin in sterile 0.9% saline
- CF1, low-dose course
- Model: Male CF1 mice; N = 10; 44 mA challenge
- Treatment course: 7 days; challenge 1 h after day 7 injection
- CF1, first phase of high-dose course
- Model: Male CF1 mice; N = 10; 44 mA challenge
- Treatment course: Days 1–12; challenges 1 h after injections on days 7 and 12
- Scn1aRH/+ course
- Model: Male Scn1aRH/+ mice, 3–5 months; N = 9; 24 mA challenge
- Treatment course: 21 days; challenges days 7, 14, 21; off-treatment challenge day 22
- Separate CF1 PD cohorts
- Model: Male CF1 mice; N = 3/group
- Treatment course: 0.5 mg/kg: 7 days; 1 mg/kg: 7 or 12 days
- Reported limits: Chronic tissue collection interval is not separately restated in this methods subsection.
Methods and source locations
Compound reported in the paper: (-)-Huperzine A; Compound label in the paper: Hup A
Literature experiment on the reported compound; no claim that the authors used or validated Adooq material.
Methods, Chronic Hup A treatment; Figure 4A–D and caption; Results, Resistance to 6 Hz-induced seizures is maintained...
CF1 6 Hz response at 44 mA: Modified Racine scale; one-way repeated-measures ANOVA and Dunn post-hoc. — Methods, Chronic Hup A treatment; Figure 4A–B and caption
Scn1aRH/+ 6 Hz response at 24 mA: Modified Racine scale; day 22 tested 24 h after last Hup A injection. — Methods, Chronic Hup A treatment; Figure 4D and Results final paragraph of chronic section
Brain AChE activity during repeat dosing in separate CF1 cohorts: Brain AChE assay in separate cohorts; no statistically significant acute-versus-chronic difference reported. — Methods, Chronic Hup A treatment; Figure 4C and corresponding Results
CF1, low-dose course · Methods, Chronic Hup A treatment; Figure 4A
CF1, first phase of high-dose course · Methods, Chronic Hup A treatment; Figure 4B
Scn1aRH/+ course · Methods, Chronic Hup A treatment; Figure 4D and chronic Results
Separate CF1 PD cohorts · Methods, Chronic Hup A treatment; Figure 4C